Daniel Reed, MD
PRIMARY APPOINTMENT:
Assistant Professor, Medicine: Hematology and Oncology
CONTACT:
PO Box 800716
UVA Div. of Hematology & Oncology
Charlottesville, VA 22908
Telephone: 434.297.9195
Fax: 434-244-7534
Email: daniel.reed@uvahealth.org
EDUCATION AND TRAINING
Primary Education
Drexel University College of Medicine
Residency
UVA
Fellowships
UVA
RESEARCH SUMMARY
Clinical trials with novel therapeutics in acute myeloid leukemia and myelodysplastic syndromes.
CLINICAL TRIALS
- Phase Ib Study of anti-CD3 x anti-CD33 Bispecific Antibody (CD33Bi) Armed Fresh Peripheral Blood Mononuclear Cells (CD33 FPBMC) in Patients with Measurable Residual Disease (MRD)+ Acute Myeloid Leukemia or Myelodysplastic Syndrome
Study Contact: Ann Brown amb8e@uvahealth.org - Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
- A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine +Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH ClinicalTrial
- A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat(MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an InadequateResponse to or are Intolerant of Hydroxyurea.
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat(MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
- Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
- A Measurable Residual Disease (Mrd) Focused, Phase II Study Of Venetoclax Plus Chemotherapy For Newly Diagnosed Younger PatientsWith Intermediate Risk Acute Myeloid Leukemia: A Tier 1 Myelomatch Clinical Trial
- A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly DiagnosedFLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial